Home | Publications | Production / Manufacturing place holder
place holder place holder

Production / Manufacturing

World Contract Research and Manufacturing Market, 2006-2011, The

Trends in Outsourcing

Publication Date   August 2006
Publisher   Visiongain
Product Type   Strategic Report
Pages   121
ISBN Number   not applicable
Product Code   VIS037
Ask a question about this product?

Price £1,499.00

approximately: $2,969 | €1,905

Summary


Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

The Contract Pharma market in 2005 was worth an estimated $57bn. Attitudes within the pharmaceutical industry are slowly changing and the use of strategic outsourcing is becoming an accepted practice. Specialised technologies and a global presence are becoming more important for a greater number of pharmaceutical companies. Even big pharma is increasingly using outsourcing to spread the risk of development and lower fixed costs.

The following issues are covered in detail:


  • A summary of the relevant recent changes in contract pharma
  • A market forecast for the world contract research and contract manufacturing markets 2006-2011
  • A discussion of relevant regulations
  • The growing importance of biotechnology outsourcing
  • A comprehensive review of review of the decision to outsourcing
  • Selected company profiles

    • Why should you buy this report?

    This report predicts that the pharmaceutical industry will undergo a period of intense change in the years to come and contract pharma services will play a large role in that change. People from all sides of the industry should read this report to keep up to date with this maturing, yet dynamic sector.

    Content


    • 1. Executive Summary
      • 1.1 Aims and Scope of Contract Pharma 2006
    • 2. Introduction to Outsourcing
      • 2.1 Contract Pharma Described
        • 2.1.1 Contract Research Organisations (CROs) and Contract Manufacturing Organisations (CMOs) Now Provide a Variety of Services
      • 2.2 Why Are Pharma Companies Interested in Contract Pharma?
        • 2.2.1 Lack of Capacity is Still the Major Reason to Outsource for Big Pharma
        • 2.2.2 Small/Mid-sized Pharma and Biotech Have a Flexible Attitude to Outsourcing
        • 2.2.3 Tactical vs. Strategic Use of Outsourcing
      • 2.3 The Changing Nature of the Pharmaceutical Market is Affecting the CRM Market
        • 2.3.1 The Rise of Generics
        • 2.3.2 Pipelines are Becoming Expensive
        • 2.3.3 The Fall of the Traditional Blockbuster
      • 2.4 Biopharmaceutical Drug Discovery and Development by Contract Pharma Companies is Set to Increase
      • 2.5 The Disadvantages of Contracting in the Pharmaceutical Industry
      • 2.6 The Future is Bright but Dynamic for the Contract Pharma Industry
    • 3. The Regulatory Aspects of Outsourcing
      • 3.1 Regulations Affecting the Organisation of Clinical Trials
        • 3.1.1 Establishing Standards for Good Clinical Practice and the International Conference on Harmonisation
        • 3.1.2 The EU Clinical Trials Directive
      • 3.2 Legal Liabilities and Regulatory Considerations in Manufacture Outsourcing
        • 3.2.1 Summary of GMP requirements
        • 3.2.2 Compliance with FDA Provisions is Vital
        • 3.2.3 EU Regulations and the Qualified Person (QP) Role
        • 3.2.4 Q7A Guidance for Active Pharmaceutical Ingredient (API) and Excipient Production
        • 3.2.5 Harmonisation of GMP Standards
      • 3.3 Globilisation helps Pharma Harmonisation
    • 4. The Outsourcing Decision
      • 4.1 Reasons to Outsource
        • 4.1.1 Outsourcing as a Tactical Decision
        • 4.1.2 Outsourcing as a Strategic Decision
      • 4.2 Cost-Benefit Analysis of Outsourcing
      • 4.3 Risks Associated with Outsourcing Incur Hidden Costs
        • 4.2.1 Errors and Delays Can Cost Millions
        • 4.2.2 Regulatory Compliance Must be Assured
        • 4.2.3 IP and Other Sensitive Data May be at Risk
        • 4.2.4 Management of Outsourcing Cannot be Ignored
      • 4.4 Tech Transfer Considerations
      • 4.5 The Virtual Company
        • 4.5.1 'Virtuality' Helps Control Spiralling Costs
        • 4.5.2 Strong Proactive Management is Key for Virtual Companies
        • 4.5.3 The Challenges of Virtual Companies are Relevant Across the Industry
      • 4.6 Key Requirements for Successful Outsourcing
        • 4.6.1 Trust and Accountability are Central to Any Outsourcing Agreement
      • 4.7 Summary: Forward Planning is the Guiding Principle for Outsourcing
    • 5. The World Outsourcing Market
      • 5.1 Market Forecast by Sector, 2005-2011
      • 5.2 Equivalent Levels of Drivers and Restraints Result in Unspectacular Growth
        • 5.2.1 Emphasis on Speed and Efficiency Benefits Contract Pharma
        • 5.2.2 Biotech and Hi-tech Pharma Require Expensive Expertise and Equipment
        • 5.2.3 Global Companies Build Trust and Reputation
        • 5.2.4 Overcapacity in Europe Increases Competition
        • 5.2.5 The Pharmaceutical Industry Still has Reservations
        • 5.2.6 Low Cost Services in India and China Drive Prices Down
      • 5.3 Summary: Growth Rates Will Vary According to Sector
    • 6. The World Market for the Contract Manufacturing Sector (2005-2011)
      • 6.1 The Market for Contract Manufacturers is Diverse
      • 6.2 API Manufacturing
        • 6.2.1 API Manufacturing and the Generics Industry
        • 6.2.2 API Manufacturers Closely Linked with Innovative Pharmaceutical Developers
        • 6.2.3 API Manufacturers Focused on Readily Available Bulk APIs
        • 6.2.4 China and India are the New Hubs for APIs
        • 6.2.5 Chinese API Export
        • 6.2.6 Western Companies Can Compete by Moving into Speciality API Manufacturing and a Guarantee of Quality
        • 6.2.7 Custom Peptides are an Opportunity for APIs to Move up the Value Chain
        • 6.2.8 The Trend for Highly Potent Ingredients Can Boost the API Market
      • 6.3 Manufacturing Finished Dosage Forms
        • 6.3.1 Solid Dosage Forms Still Constitute the Majority of the Dosage Form Market
        • 6.3.2 CMOs Venture into Development and Product Extensions
      • 6.4 The World API Market Will Grow Slowly
      • 6.5 Contract Manufacturing of Finished Dosage Forms
      • 6.6 Different Models for CMOs
        • 6.6.1 DSM Represents a Traditional Approach to Chemical Contract Manufacturing
        • 6.6.2 Lonza Mixes Exclusive Synthesis and Biotech with Bulk Production
        • 6.6.3 Patheon Moves into Process Development to Secure Early Phase Contracts
    • 7. Outsourcing Biotech Manufacturing
      • 7.1 History of the Biotech Contract Manufacturing Industry
        • 7.1.1 Failure of Early Efforts in Contract Biologic Manufacturing
        • 7.1.2 Barriers Existed to Contract Biologic Manufacture in the 1990s
        • 7.1.3 Biologics License Application
      • 7.2 Cost Benefits of Outsource Manufacturing in Biotech
      • 7.3 The Future of Biotech Outsourcing
    • 8. The World Market for Contract Research (2005-2011)
      • 8.1 A Lack of Innovative Drugs Puts Pressure on the Pipeline
      • 8.2 The World Pharma Market is Heading for Low Growth
      • 8.3 The Clinical Trials Market Leads R&D Outsourcing
        • 8.3.1 Clinical Trials are an Obvious Target for Outsourcing
      • 8.4 The Drive for Patient Recruitment has Pushed Clinical Trials East
        • 8.4.1 Strengths of Outsourcing Clinical Trials in Developing Countries
        • 8.4.2 Weaknesses of Outsourcing Clinical Trials in Developing Countries
      • 8.5 The Clinical Trials Market Will Continue to Grow
        • 8.5.1 Clinical Trials Market by Region
        • 8.5.2 The Clinical Trials Markets in India and China Will Increase
      • 8.6 Key Technological Advances Promise to Transform Clinical Research
        • 8.6.1 EDC Can Streamline Clinical Trials
        • 8.6.2 Training and Security are Barriers to EDC Conversion
        • 8.6.3 Pharmacogenomics has the Potential to Revolutionise the Pharmaceutical Industry
        • 8.6.4 The Progress of Pharmacogenomics Has Been Slow
        • 8.6.5 Identification of Expression Profiles in Pre-clinical Models
        • 8.6.6 Phase I and II Clinical Trials Will Incorporate More Complex Screening Techniques
      • 8.7 Safety Concerns and Development Pressures Will Change the Structure of Clinical Trials
      • 8.8 The Use of CROs in Drug Discovery and Development is Increasing as Big Pharma Changes
        • 8.8.1 Contract Research has an Increasing Role in Lifecycle Management
      • 8.9 The Contract Research Market is Dominated by a Few Companies
      • 8.10 Quintiles is the Leading CRO
      • 8.10.1 A Global Company is Required for Global Trials
      • 8.10.2 Sale of Business Units Indicates a Strong Emphasis on Late Phase Trials
      • 8.11 Covance Successfully Combines Pre-clinical Research with Late Phase Organisation
    • 9. Other Areas to Outsource
      • 9.1 Outsourcing Sales and Marketing Brings Flexibility
        • 9.1.1 An Integrated Approach Will Help Sustain the Contract Sales Market
      • 9.2 Contract Packaging Services
        • 9.2.1 Contract Packaging is Not Just Boxes
        • 9.2.2 Advantages Offered by Contract Packaging Organisations
      • 9.3 Outsourced Biostorage Becomes a Strategic Consideration
      • 9.4 Forward Planning is Required for Regulatory Affairs Outsourcing
      • 9.5 Electronic Data Management
      • 9.6 Heightened Safety Attention Opens the Door to Contract Pharmacovigilance
    • 10. Conclusion
      • 10.1 The Contract Pharma Industry is Maturing
      • 10.2 The Lines of Distinction are Blurring
      • 10.3 Contract Pharma Companies Must be Willing to Change to Survive in the Market
    • List of Tables
      • Table 2.1 Reasons Given for Pharmaceutical Outsourcing
      • Table 2.2 Biotech Drugs in Late Development for Leading Pharmaceutical Companies, 2006
      • Table 5.1 World Market Forecast ($bn) for the Contract Pharma Market, 2005-2011
      • Table 6.1 World API Market by Region, 2004
      • Table 6.2 Leading Chinese Exported APIs, 2005
      • Table 6.3 The World Market Forecast for APIs, 2005-2011
      • Table 6.4 The World Market Forecast for Finished Dosage Forms, 2005-2011
      • Table 6.5 Lonza Revenue ($m) by Service Activity, 2005
      • Table 6.6 Lonza Worldwide Manufacturing Capacity (Pharmaceutical), 2005
      • Table 6.7 Patheon Worldwide Manufacturing Capacity, 2005
      • Table 6.8 Patheon Revenue ($m) and Growth Rates (%), 2002-2005
      • Table 6.9 Patheon Revenue ($m) by Service Activity, 2005
      • Table 8.1 The World Pharmaceutical Market by Region, 2005
      • Table 8.2 Clinical Trials Revenue ($m), 2004-2011
      • Table 8.3 Assessment of EDC Solutions
      • Table 8.4 Leading CROs by Total Revenue ($m), 2004-2005
      • Table 8.5 Leading CROs by Clinical Trial Revenue ($m) Only, 2004-2005
      • Table 8.6 Growth of Covance Revenues ($m) for Early and Late Development, 2002-2005
    • List of Figures
      • Figure 2.1 Common Examples of Contract Services During Drug Lifecycle
      • Figure 2.2 The Role of Contract Pharma Organisations n Drug Development
      • Figure 2.3 Comparison of R&D Costs and the Number of Approved NMEs
      • Figure 2.4 Predicted Spending on Outsourcing by the Pharmaceutical Industry, 2006
      • Figure 5.1 World Market Forecast for the Main Sectors of the Contract Pharma Market, 2005-2011
      • Figure 5.2 The Contract Pharma Industry, 2005
      • Figure 6.1 Market Share (%) of the Chinese API Market by Class, 2005
      • Figure 6.2 Global Distribution of Chinese API Exports, 2005
      • Figure 6.3 Global Revenues for APIs, 2005-2011
      • Figure 6.4 Global Revenues for Finished Dosage Forms, 2005-2011
      • Figure 6.5 Total Revenues from DSM Services, 2005
      • Figure 6.6 DSM Revenue by Business Sector, 2005
      • Figure 6.7 Revenues from DSM Life Sciences
      • Figure 6.8 Lonza Total Revenues, 2002-2005
      • Figure 6.9 Patheon Revenue by Geographic Region, 2005
      • Figure 8.1 Growth Rate (%) for the World Pharmaceutical Market, 2000-2005
      • Figure 8.2 Revenues ($m) from The Clinical Trials Market, 2004-2011
      • Figure 8.3 Revenues ($m) of the Clinical Trials Industry by Region, 2004-2011
      • Figure 8.4 Clinical Trial Market Share by Region, 2004
      • Figure 8.5 Clinical Trial Market Share by Region, 2011
      • Figure 8.6 Top Ten CROs by Clinical trials Market Share (%), 2005
      • Figure 8.7 Revenues ($m) from Quintiles Developmental Services Group 2002-2005
      • Figure 8.8 Growth Rate (%) for Quintiles Clinical Services Revenues, 2003-2005
      • Figure 8.9 Revenues ($m) for Covance, 2002-2005